Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in ...

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations ...

Sandoz launches ustekinumab biosimilar, Pyzchiva autoinjector in Europe: Basel Saturday, May 24, 2025, 12:00 Hrs [IST] Sandoz, one of the global leaders in generic and biosimilar ...

US FDA approves Bio-Thera Solutions & Hikma Pharma’s Starjemza injection, a biosimilar referencing Stelara injection: Guangzhou Wednesday, May 28, 2025, 17:00 Hrs [IST] Bio-Ther ...

This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

Market LaunchFormycon and Fresenius Kabi announce the commercial launch of FYB202/Otulfi™, an approved ustekinumab biosimilar in Canada 27.05.2025 / 14:30 CET/CESTThe issuer is solely responsible for ...

The U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for Celltrion’s YUFLYMA.

Metabolic syndrome is associated with elevated levels of pain catastrophizing among patients with PsA and may impact disease activity.

Researchers comparing two injections commonly used to relieve knee pain from osteoarthritis—corticosteroid and hyaluronic acid—found that corticosteroid injections were associated with higher ...

Some Michigan hospitals are marking up prices by thousands of dollars above what they pay manufacturers for certain prescription drugs, according to a new report from the Michigan Health Purchasers ...